Price
$46.29
Increased by +5.59%
Dollar volume (20D)
68.93 M
ADR%
1.61
Earnings report date
Feb 6, 2024
Shares float
226.49 M
Shares short
2.42 M [1.07%]
Shares outstanding
228.18 M
Market cap
10.20 B
Beta
0.44
Price/earnings
30.83
20D range
42.73 46.55
50D range
37.90 46.55
200D range
34.74 47.70

QIAGENN. V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.

The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables.

Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.

It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.

The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Reported date EPSChange YoY EstimateSurprise
Jun 17, 24 0.46
Decreased by -9.80%
0.44
Increased by +4.55%
Feb 6, 24 0.55
Increased by +3.77%
0.55
Oct 30, 23 0.50
Decreased by -5.66%
0.48
Increased by +4.17%
Aug 8, 23 0.51
Increased by 0.00%
0.50
Increased by +2.00%
May 3, 23 0.51
Decreased by -36.25%
0.47
Increased by +8.51%
Feb 7, 23 0.53
Decreased by -28.38%
0.47
Increased by +12.77%
Nov 7, 22 0.53
Decreased by -8.62%
0.45
Increased by +17.78%
Jul 28, 22 0.51
Decreased by -23.88%
0.46
Increased by +10.87%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 475.89 M
Decreased by -4.75%
77.82 M
Decreased by -5.55%
Increased by +16.35%
Decreased by -0.84%
Jun 30, 23 494.86 M
Decreased by -4.01%
80.79 M
Decreased by -16.42%
Increased by +16.33%
Decreased by -12.93%
Mar 31, 23 485.40 M
Decreased by -22.76%
85.03 M
Decreased by -45.25%
Increased by +17.52%
Decreased by -29.12%
Dec 31, 22 497.98 M
Decreased by -14.49%
88.84 M
Decreased by -31.23%
Increased by +17.84%
Decreased by -19.57%
Sep 30, 22 499.63 M
Decreased by -6.57%
82.39 M
Decreased by -38.11%
Increased by +16.49%
Decreased by -33.76%
Jun 30, 22 515.51 M
Decreased by -9.13%
96.66 M
Decreased by -20.15%
Increased by +18.75%
Decreased by -12.13%
Mar 31, 22 628.39 M
Increased by +10.79%
155.31 M
Increased by +20.19%
Increased by +24.72%
Increased by +8.49%
Dec 31, 21 582.40 M
Increased by +1.95%
129.19 M
Decreased by -39.26%
Increased by +22.18%
Decreased by -40.42%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY